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Abstract
Background: This was a part of LIMPRINT (Lymphoedema IMpact and PRevalence—INTernational), an
international study aimed at capturing the size and impact of lymphedema and chronic edema in different
countries and health services across the world. The purpose of this study was to clarify the prevalence and the
impact of chronic edema in Japan.
Methods and Results: This was a two-phase facility-based study to determine the prevalence and functional
impact of chronic edema in the adult population in Japan between 2014 and 2015. The prevalence study
involved a university hospital, an acute community hospital, and a long-term medical facility. The impact study
involved six facilities, including two outpatient clinics in acute care hospitals (one led by a physician and the
other led by a nurse), inpatient wards in two acute care hospitals, and two nursing home/long-term care
facilities. Various questionnaires and clinical assessments were used to gather patient demographic data and
assess the functional impact of chronic edema. The results showed that chronic edema was much more prevalent
in the long-term care facility than in acute care hospitals; cellulitis episodes occurred in*50% of cases in the
gynecologist-led outpatient clinic, even though >80.0% of patients received standard management for edema;
edema was found in the trunk region, including the buttock, abdomen, and chest-breast areas, in addition to the
upper and lower limbs; and subjective satisfaction with edema control was low, even though the quality-of-life
scores were good.
Conclusions: The prevalence of chronic edema varied according to the facility type, ranging from 5.0% to
66.1%. The edema was located in all body parts, including the trunk region. Subjective satisfaction with control
of edema was poor, while general quality of life was good. This large health care issue needs more attention.
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Both lymphedema and chronic edema have strongnegative effects on not only patients’ health statuses but
also medical expenditures around the world, but the precise
epidemiological data and its impact have not been fully
elucidated. This study was a part of LIMPRINT (Lymphoe-
dema IMpact and PRevalence—INTernational), an interna-
tional study aimed at capturing the size and impact of
lymphedema and chronic edema in different countries and
health services across the world. Its focus is to provide evi-
dence to support the development and reimbursement of
lymphedema services. The project is coordinated by Pro-
fessor Christine Moffatt from the International Lymphoede-
ma Framework (ILF). The ILF is a UK charity, whose aim is
to improve the management of chronic edema and related
disorders worldwide through the sharing of expertise and
resources and by supporting individual countries to develop a
long-term strategy for the care and management of chronic
edema. Further details of the LIMPRINT project can be ob-
tained on the ILF website (www.lympho.org/limprint). This
study used the multicenter data gathered between 2014 and
2016 through the ILF, Japan branch.
In Japan, there is only a reimbursement system under na-
tional health insurance for lymphedema management of pa-
tients diagnosed with lymphedema after the treatment of
uterine cancer, uterine adnexal cancer, prostate cancer, or
breast cancer with lymph node dissection.1 However, there is
no such system for chronic edema. This is partly because of
the lack of epidemiological studies on chronic edema to un-
derstand its impact on patients’ health.
Aim
The purpose of this study was to clarify the prevalence and
impact of chronic edema in Japan.
Methods
Study design. This was a facility-based study to deter-
mine the prevalence and functional impact of chronic edema
in the adult population within the ILF, Japan. LIMPRINT in
Japan was a two-phase project conducted between 2014 and
2015, which included a prevalence study and an impact
study.
Prevalence study
Setting. In this study, all hospitalized patients at all ap-
propriate wards were investigated to identify patients with
chronic edema (excluding children <18 years and the De-
partment of Psychiatry) on a specific day. The facilities
were a university hospital (n = 600, 31 medical depart-
ments), an acute community hospital (n = 195, 13 medical
departments), and a long-term medical facility (n = 310, 5
medical departments).
Definition and assessment of chronic edema. To deter-
mine the prevalent cases of chronic edema, patients whose
edema continued over 3 months based on interviews and
medical chart reviews were defined as having chronic edema.
First, the chief investigators in cooperation with in-charge
nurses at each facility assessed chronic edema by inspection.
If it was difficult to determine the presence of chronic edema
by inspection, the AFTD-pitting test was used.2 AFTD is an
acronym derived from the four factors used for the test:
Anatomical locations of edema assessment; Force required to
pit; the amount of Time; and the Definition of edema.
Analysis. The prevalence of chronic edema was calcu-
lated by dividing the number of patients with chronic edema
by the total number of inpatients, and 95% confidence in-
tervals (CIs) were also calculated.
Impact study
Setting. Six facilities, including two outpatient clinics in
acute care hospitals (one led by a physician and the other led
by a nurse), inpatient wards in two acute care hospitals, and
two nursing home/long-term care facilities, participated in
this study. The two outpatient clinics specialized in lym-
phedema management led by a gynecologist or a nurse cer-
tified as a lymphedema therapist. Two wards in a university
hospital and a community hospital participated in the prev-
alence study. In the university hospital, the breast surgery
department, gynecology department, and rehabilitation de-
partment follow up lymphedema patients with timely referral
to a clinical nurse specialist in cancer nursing and a certified
expert nurse in breast cancer care. In a community hospital, a
clinical nurse specialist in cancer nursing with lymphedema
therapist certification and a general nurse conduct their own
outpatient clinic for lymphedema patients that sees patients
once a week. The long-term care facilities do not have a
special system for chronic edema management.
The patient inclusion criteria were as follows: older than
18 years; swelling for longer than 3 months; and able to
understand the study as set out in the information sheet and
give informed consent. The patient exclusion criteria were as
follows: unwilling or unable to participate for whatever
reason; receiving end-of-life care; and not considered to be in
the patient’s best interest to participate, as decided by the lead
clinician.
Data collection. A random sample could be obtained in two
facilities; the two wards from the university hospital and the
community hospital with chronic edema were identified due to
limited resources. A random permuted block design allowed for
a one third sample to be taken. In the long-term care facility, the
investigators collected data from all participants. In the outpa-
tient clinic, participants who had an appointment for the service
on that day were included in the survey.
Questionnaire survey. Questionnaires developed by the
ILF were translated into Japanese followed by back translation
to English for validation. The core tool was used to gather
patient demographic data, and module tools were used to col-
lect data on various aspects of the patients. The module tools
assessed the functional impact of chronic edema and required
completion through contact with the patient and clinical as-
sessment where required. The module tools included demo-
graphic and disability (World Health Organization Disability
Assessment Schedule 2.0 [WHODAS 2.0]), Quality of Life
(QOL; Lymphoedema Quality of Life Study [LYMQOL] and
EuroQol 5 Dimension [EQ-5D]), and details of swelling,
wounds, and cancer.
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WHODAS 2.0, a generic assessment instrument for health
and disability, was used to assess six domains of functioning,
including cognition, mobility, self-care, getting alone, life
activities, and participation, with four possible response op-
tions (0= none, 1=mild difficulty, 2 =moderate difficulty,
3 = severe difficulty, and 4 = extreme difficulty or cannot do).
The overall functioning score was calculated according to the
guideline provided by the World Health Organization
(WHO).3 The scores for each item were summed up, and then
the total score was divided by 48. A higher score indicates a
more severe disability status.
The EQ-5D, which is a generic health-related QOL profile
instrument developed for measuring utility, was used.4 It contains
five domains: mobility, self-care, usual activities, pain/discom-
fort, and anxiety/depression. A single answer with three possible
response options (1 = no problem, 2 = some/moderate prob-
lems, and 3 = extreme problems) was required. The EQ-5D
has been found to be sensitive to the effect of lymphedema on
health related quality of life.5 The Japanese version was
validated for the Japanese general population.6 Scores from
the five domains were combined into a single utility score
between -0.594 (worst possible state) and 1.000 (best pos-
sible state) based on the Japanese weighting system.7 The
perceived current health state is measured by asking re-
spondents to indicate their current health state on a Visual
Analogue Scale with endpoints labeled 0 ‘‘Worst imaginable
health state’’ and 100 ‘‘Best imaginable health state.’’
The LYMQOL was used to determine the level of QOL
related to lymphedema.8,9 This scale was developed to as-
sess condition-specific QOL of patients with lymphedema
of the limbs. The questions cover four domains (symptoms,
body image/appearance, function, and mood) with four
possible response options (1 = not at all, 2 = a little, 3 = quite
a bit, and 4 = a lot). Scores for each domain were calculated
according to the previous article.8 A higher LYMQOL score
indicates a lower QOL. For overall QOL related to lym-
phedema, the responder can pick one item from 0 ( = poor)
to 10 ( = excellent).
Analysis. Data were analyzed according to the four types
of facilities involved: a gynecologist-led outpatient clinic, a
lymphedema therapist nurse-led outpatient clinic, an acute
care hospital ward, and a long-term care facility. Descriptive
data are expressed as N (%) for categorical variables and
medians (interquartile range) for continuous variables. The
prevalence study determined the point prevalence in each
facility. In the impact study, the data are presented according
to the facility type. The facilities were classified into four
groups: outpatient clinic, inpatient ward, nursing home, and
long-term care facilities.
Ethical considerations. The study protocol was approved
by the Medical Ethics Committee of Kanazawa University.











Age (years) 72 (68–74) 68 (59–74) 59.5 (50–72) 85 (80–90)
Sex
Male 0 (0.0) 1 (5.0) 4 (40.0) 7 (23.3)
Female 51 (100.0) 19 (95.0) 6 (60.0) 23 (76.7)
BMI (kg/m2)
<18.5 2 (3.9) 0 (0.0) 3 (30.0) 6 (20.0)
18.5 to <25.0 30 (58.8) 12 (60.0) 5 (50.0) 23 (76.7)
25.0 to <30.0 14 (27.5) 8 (40.0) 2 (20.0) 1 (3.3)
‡30.0 5 (9.8) 0 (0.0) 0 (0.0) 0 (0.0)
Upper limb mobility
Full range of movement 50 (98.0) 17 (85.0) 9 (90.0) 14 (46.7)
Limited range of movement 1 (2.0) 1 (5.0) 0 (0.0) 1 (3.3)
No function 0 (0.0) 2 (10.0) 1 (10.0) 0 (0.0)
Lower limb mobility
Walks unaided 50 (98.0) 20 (100.0) 5 (50.0) 6 (20.0)
Walks with aid 1 (2.0) 0 (0.0) 1 (10.0) 13 (43.3)
Chair bound 0 (0.0) 0 (0.0) 3 (30.0) 8 (26.7)
Bed bound 0 (0.0) 0 (0.0) 1 (10.0) 3 (10.0)
Immobility 0 (0.0) 0 (0.0) 2 (20.0) 29 (96.7)
Comorbidity
Diabetes mellitus 4 (7.8) 3 (15.0) 2 (20.0) 7 (23.3)
Heart failure and/or
ischemic heart disease
0 (0.0) 1 (5.0) 1 (10.0) 3 (10.0)
Neurological disorder 2 (3.9) 1 (5.0) 0 (0.0) 1 (3.3)
Peripheral arterial disease 0 (0.0) 3 (15.0) 0 (0.0) 0 (0.0)
N (%), median (interquartile range).
BMI, body mass index.
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Informed consent was obtained from each of the patients or
their proxies.
Results
Prevalence of chronic edema
The prevalence of chronic edema was 5.0% (95% CI:
3.2%–6.8%; 30/600) in the university hospital, 7.7% (95%
CI: 3.8%–11.6%; 15/195) in the acute community hospital,
and 66.1% (95% CI: 60.9%–71.4%; 205/310) in the long-
term medical facility; the median ages were 67.7, 70.2, and
87.2 years, respectively.
Impact of chronic edema
In total, 111 patients were investigated for the impact of
chronic edema, and the data were analyzed in each facility, the
gynecologist-led outpatient clinic (n= 51), the lymphedema
therapist nurse-led outpatient clinic (n= 20), the acute care
hospital ward (n= 10), and the long-term care facility (n= 30).
The median patient age was 65 years, with over 95% of
outpatients being female in both facilities. Inpatients of the acute
care hospital ward were 59.5 years of age, with 60% female, and
those at the long-term care facility were 85 years of age, with
76.7% female. In addition, 0% of outpatients and 96.7% of long-
term care facility residents were immobile (Table 1).










facility (n = 30)
Classification of edema
Primary lymphedema 2 (3.9) 0 (0.0) 0 (0.0) 0 (0.0)
Secondary lymphedema 49 (96.1) 18 (90.0) 4 (40.0) 0 (0.0)
Unknown 0 (0.0) 2 (10.0) 6 (60.0) 30 (100.0)
Secondary swelling due to cancer
Breast cancer 13 (25.5) 10 (50.0) 3 (30.0) —
Endometrial/cervical cancer 24 (47.1) 8 (40.0) 0 (0.0) —
Gastric/liver/colorectal cancer 2 (3.9) 0 (0.0) 1 (10.0) —
Others 12 (23.5) 2 (10.0) 6 (60.0) —
Treatment of lymphatic obstruction 49 (96.1) 20 (100.0) 4 (40.0) 0 (0.0)
Duration of edema
3–6 Months 1 (2.0) 1 (5.0) 7 (70.0) 4 (13.3)
6 Months to 1 year 1 (2.0) 3 (15.0) 2 (20.0) 8 (26.7)
1–2 Years 2 (3.9) 2 (10.0) 0 (0.0) 3 (10.0)
2–5 Years 9 (17.6) 5 (25.0) 0 (0.0) 4 (13.3)
5–10 Years 23 (45.1) 5 (25.0) 1 (10.0) 4 (13.3)
>10 Years 15 (29.4) 4 (20.0) 0 (0.0) 7 (23.3)
Cellulitis 25 (49.0) 3 (15.0) 3 (30.0) 4 (13.3)
Infection 9 (17.6) 2 (10.0) 1 (10.0) 4 (13.3)
Hospitalization due to cellulitis 0 (0.0) 1 (5.0) 1 (10.0) 1 (3.3)
Infection, number of times
0 42 (82.4) 18 (90.0) 9 (90.0) 26 (86.7)
1 5 (9.8) 2 (10.0) 0 (0.0) 3 (10.0)
2 2 (3.9) 0 (0.0) 1 (10.0) 0 (0.0)
3 2 (3.9) 0 (0.0) 0 (0.0) 1 (3.3)
Skin care advice 48 (94.1) 19 (95.0) 3 (30.0) 0 (0.0)
Wound dressing use 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.3)
Antibiotic use 13 (25.5) 0 (0.0) 0 (0.0) 1 (3.3)
Massage 51 (100.0) 16 (80.0) 1 (10.0) 11 (36.7)
Physiotherapy 0 (0.0) 0 (0.0) 0 (0.0) 13 (43.3)
Compression garment 49 (96.1) 20 (100.0) 4 (40.0) 0 (0.0)
Multi-layer bandage 34 (66.7) 15 (75.0) 1 (10.0) 0 (0.0)
Pneumatic compression pumps 0 (0.0) 0 (0.0) 1 (10.0) 1 (3.3)
Debulking lymphedema (lymphatic surgery) 7 (13.7) 1 (5.0) 0 (0.0) 0 (0.0)
Main categories of treatment within Complex
Decongestive Therapy
Exercise advice 40 (80.0) 17 (85.0) 1 (0.0) 0 (0.0)
Cellulitis advice 49 (98.0) 19 (95.0) 1 (0.0) 0 (0.0)
Psychological support 43 (86.0) 10 (50.0) 0 (0.0) 0 (0.0)
Subjective control of chronic edema: in your
opinion, is the swelling well controlled?
23 (46.0) 10 (50.0) 5 (50.0) 13 (43.3)
N (%).
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Lymphedema conditions in each facility are shown in
Table 2. Except for two cases, they all had secondary lym-
phedema. Duration of edema was 5–10 years in 23 cases
(46%) in the gynecologist-led clinic and 5 cases (25.0%) in
the nurse-led clinic, and the duration was 3–6 months in 7
cases (70.0%) in the acute care hospital, while the duration of
chronic edema ranged from 36 months to over 10 years in the
patients in the long-term care medical facility. Overall, 25
cases (50%) had a history of cellulitis, with 2 cases (3.9%)
having 2 episodes and 2 cases (3.9%) having 3 episodes in the
gynecologist-led clinic. In each outpatient clinic, over 80% of
patients received standard lymphedema care, including skin
care advice, massage, multilayer garment, and exercise ad-
vice. Positive subjective opinions regarding the quality of
edema control ranged from 43.3% to 50.0% in all facilities.
The relevant anatomical locations of chronic edema for
both sides of the whole body are summarized in Table 3. Of
all the body parts, chronic edema was most common in the
lower limb, foot, lower leg, and upper leg. Table 4 shows
lymphedema status for outpatients in acute care hospitals.
Upper lymphedema patients at International Society of
Lymphology (ISL) stage II accounted for 69.2% of cases in
the gynecologist-led and 70.0% in the nurse-led outpatient
clinics. Lower lymphedema patients at ISL late stage II ac-
counted for 63.2% of cases in the gynecologist-led and 40.0%
in the nurse-led outpatient clinics. There were no wounds in
the affected edema sites in these subjects.
Table 5 shows the generic and disease-specific QOL status
assessed by WHODAS 2.0, EQ-5D, and LYMQOL for the
upper and lower limbs, respectively.
Discussion
There were four new findings in this study. First, the prev-
alence of chronic edema was much higher in the long-term care










facility (n = 60)
Head, neck, and face 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Upper limbs
Fingers 10 (9.8) 8 (20.0) 1 (5.0) 1 (1.7)
Hand 10 (9.8) 8 (20.0) 2 (10.0) 2 (3.3)
Lower arm 13 (12.7) 10 (25.0) 3 (15.0) 3 (5.0)
Upper arm 12 (11.8) 11 (27.5) 1 (5.0) 2 (3.3)
Shoulder 4 (3.9) 8 (20.0) 0 (0.0) 1 (1.7)
Lower limbs
Toes 31 (30.4) 4 (10.0) 5 (25.0) 11 (18.3)
Foot 40 (39.2) 9 (22.5) 13 (65.0) 28 (46.7)
Lower leg 41 (40.2) 12 (30.0) 14 (70.0) 23 (38.3)
Upper leg 43 (42.2) 11 (27.5) 10 (50.0) 3 (5.0)
Trunk
Buttock 21 (20.6) 4 (0.0) 4 (20.0) 0 (0.0)
Abdomen 20 (19.6) 0 (0.0) 4 (20.0) 0 (0.0)
Upper chest-breast 2 (2.0) 0 (0.0) 0 (0.0) 0 (0.0)
Genital area (vulva,
scrotum, and penis)
2 (2.0) 0 (0.0) 0 (0.0) 0 (0.0)
N (%), numbers show both sides of each body part. Physician: gynecologist.
Table 4. Lymphedema Status of Outpatients in Acute Care Hospitals










Present 2 (15.4) 20 (52.6) 7 (70.0) 5 (50.0)
Absent 11 (84.6) 18 (47.4) 3 (30.0) 5 (50.0)
ISL classification
ISL stage I 2 (15.4) 1 (2.6) 0 (0.0) 0 (0.0)
ISL stage II 9 (69.2) 11 (28.9) 7 (70.0) 4 (40.0)
ISL stage late II 2 (15.4) 24 (63.2) 3 (30.0) 4 (40.0)
ISL stage III 0 (0.0) 2 (5.3) 0 (0.0) 1 (10.0)
N (%).
ISL, International Society of Lymphology.
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facility than in the acute care hospitals. Second, the prevalence
of cellulitis episodes was *50% in the gynecologist-led out-
patient clinic, even though over 80.0% of the patients under-
went standard management for edema. Third, the edema could
be found in the trunk region, including the buttock, abdomen,
and chest-breast areas, in addition to the upper and lower limbs.
Fourth, subjective satisfaction with control of edema was low,
even though the QOL scores were good.
The prevalence of chronic edema was much higher among
patients in a long-term medical facility (66.1%) with median
age of 87.2 years than in both acute hospitals, including a
university hospital (5.0%; median age 67.7 years) and a com-
munity hospital (7.7%; median age 70.2 years). According to
the previous prevalence study of chronic edema, Moffatt et al.
reported that, while chronic edema/lymphedema can occur at
any age, there was a clear increase in the rate with age.10,11
Japan is already a super-aged society: the 2017 statistics
showed an older adult population of*28% and an average life
expectancy of*80.7 years in men and 87.0 years in women.12
In Japan, more attention to edema management for elderly
people is needed.
In these results, the highest prevalence of cellulitis epi-
sodes was 49.0% in the gynecologist-led outpatient clinic
compared to other facilities, ranging from 15.0% to 30.0%.
In the gynecologist-led outpatient clinic, over 80.0% of
patients received standard management for lymphedema,
such as skin care advice (94.1%), massage (100.0%),
compression garments (96.1%), exercise advice (80.0%),
and cellulitis advice (98.0%), which are known as best
practices.13 The reason why the number of cellulitis epi-
sodes was high despite standard care in the gynecologist-led
clinic was the larger numbers of lower lymphedema patients
(n = 38) and late II patients (63.2%) than in the nurse-led
clinic. Lower limb lymphedema and its severity are factors
related to cellulitis.14 Further investigation (e.g., frequency
and methodology of management, and patient compliance)
is needed to clarify the details that potentially prevent cel-
lulitis episodes in these patients.
This study also showed that edema can be found in the
trunk region. In the gynecologist-led outpatient clinic,
chronic edema was found in the buttock, abdomen, and upper
chest-breast areas. Previous studies have not provided the
details of the regions affected by chronic edema in outpatient
clinics. Further investigation of the details of the care pro-
vided to the chronic edema in those regions is needed.
Generic QOL scores in lymphedema outpatients were
88.8%–100.0%, a relatively good status compared to inpa-
tients at an acute care hospital (71.7%). It is quite interesting
to note that the utility score in patients at outpatient clinics
was extremely high (0.796–1.000). Professional-led clinics
can offer optimal options for lymphedema management that
can preserve patients’ functional status, leading to a high
utility score. However, subjective satisfaction with control of
chronic edema was only 46.6% or 50.0% in both outpatients
and inpatients. These results might be explained by the fact
that health-related QOL status was not directly affected by
subjective satisfaction with edema control. Further study will
be needed to improve these subjective satisfaction ratings.
This study has two limitations. First, this investigation was
a facility-based study, not community based. Therefore, it
will not be compared to other community-based studies in
LIMPRINT. Second, the questionnaires related to QOL were
not suitable for elderly inpatients due to cognitive dysfunc-
tion and dementia. Therefore, questionnaires for these sub-
jects might need to be developed.
Conclusion
This LIMPRINT Japan branch survey investigated the
prevalence of chronic edema in various care settings and its
impact using a detailed questionnaire. The prevalence of
chronic edema varied according to the facility type, ranging
from 5.0% to 66.1%. The edema was located in all body parts,
including the trunk region. Subjective satisfaction with con-
trol of edema was poor, while general QOL was good. This
large health care issue needs more attention.
Table 5. Disease-Specific Quality-of-Life Status in Acute Care Hospitals
Outpatients
Inpatients (n= 10)Physician led (n = 51) Nurse led (n = 20)
WHODAS 2.0 0.0 (0.0–10.4) 2.1 (0.0–3.1) 58.3 (37.5–72.9)
EQ-5D
Utility score 1.000 (0.796–1.000) 0.796 (0.796–1.000) 0.516 (0.312–1.000)
Perceived health status 88.0 (88.0–100.0) 100 (99.6–100.0) 71.7 (60.0–100.0)
LYMQOL: upper limb n = 13 n= 10 n = 1
Function 1.2 (1.0–2.2) 1.45 (1.2–2.0) 2.0
Appearance 1.8 (1.0–2.6) 1.7 (1.4–2.2) 1.4
Symptom 2.3 (1.7–2.7) 1.9 (1.5–2.3) 3.0
Mood 1.0 (1.0–2.0) 1.9 (1.0–2.5) 2.8
Overall 8.0 (7.0–9.0) 7.25 (6.0–8.0) 4.0
LYMQOL: lower limb n = 38 n= 10 n = 9
Function 1.6 (1.1–2.3) 1.5 (1.1–2.0) 2.8 (2.5–2.8)
Appearance 2.3 (1.2–2.8) 2.2 (1.3–2.8) 2.2 (2.0–2.3)
Symptom 2.0 (1.3–2.7) 1.9 (1.7–2.2) —
Mood 2.0 (1.7–2.3) 1.3 (1.0–2.0) 2.8 (2.5–3.0)
Overall 8.0 (6.0–8.0) 7.5 (6.0–8.0) 5.0 (4.0–6.0)
Median (interquartile range).
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